Andere Sprachen Incannex Healthcare Inc.

Aktien

A3ERT8

US45333F1093

IXHL

Realtime-Estimate Cboe BZX Andere Börsenplätze 21:32:50 23.05.2024			% 5 Tage	% 1. Jan.
2.585 ^USD	-3.90%		-8.27%	-45.04%

07.05.	Incannex schließt erfolgreiches Pre-Ind-Meeting mit der FDA für Cannquit-O zur Behandlung von Opioidkonsumstörungen ab	CI
05.03.	Incannex Healthcare Inc. kündigt Änderungen in der Geschäftsführung an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder	07.05.
Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder	07.05.
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)	01.05.
Incannex Healthcare Inc. Quarterly Update, Q1 2024	16.04.
Incannex Healthcare Inc. Announces CFO Changes	05.03.
Incannex Healthcare Inc. Announces Executive Changes	05.03.
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	28.02.
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	28.02.
Incannex Healthcare Completes Pre-Investigational New Drug Meeting on CannQuit-N With US FDA	16.02.
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation	16.02.
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N	16.02.
Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14.02.
Clarion Clinics Open for Psychedelic-Assisted Treatments	01.02.
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	24.01.
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	24.01.
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences	18.01.
Incannex Completes Dosing and Therapy in Phase 2 ?Psigad? Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder	18.01.
Incannex Healthcare Gets Institutional Review Board Approval For IHL-42X Drug Trial	17.01.
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	17.01.
Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	17.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Incannex Healthcare Inc.

Aktien

A3ERT8

US45333F1093

IXHL

Andere Sprachen

Filter